Current Status of Clozapine for Treatment-Resistant Schizophrenia / 대한정신분열병학회지
Korean Journal of Schizophrenia Research
;
: 1-7, 2021.
Article
in Korean
| WPRIM
| ID: wpr-902516
ABSTRACT
Clozapine is the first and most effective atypical antipsychotic drug for treatment-resistant schizophrenia (TRS). After withdrawal of clozapine due to concerns of agranulocytosis, clozapine was reintroduced with a comprehensive safety monitoring system, the clozapine patient monitoring system (CPMS). The reintroduction was a response to the pressure from psychiatrists and patients with TRS and their families. Clozapine is still the best single agent for the treatment of TRS. However, approximately 30% of patients with TRS still show psychotic symptoms. In patients with clozapine-resistant schizophrenia (CRS), augmentation of other antipsychotic agents could be considered after a thorough evaluation of proper clozapine treatment. In this review, the status of clozapine in patients with TRS and CRS will be discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Korean
Journal:
Korean Journal of Schizophrenia Research
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS